UB Paderborn / Katalog / Suche / in CDI

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment, 2020-04, Vol.958, p.162794, Article 162794

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.176-178

2020

Link zum Volltext

Verfügbarkeit prüfen

EP1311: LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FOLLOWING A SIMPLIFIED PROACTIVE DRUG MONITORING ALGORITHM DURING INDUCTION TREATMENT WITH INFLIXIMAB (IFX)

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1097

2022

Link zum Volltext

Verfügbarkeit prüfen

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1137-S-1138

2019

Link zum Volltext

Verfügbarkeit prüfen

Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy

Inflammatory bowel diseases, 2021-02, Vol.27 (2), p.224-235

2021

Link zum Volltext

Verfügbarkeit prüfen

P430 The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i883-i884

2024

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting

Rheumatology and therapy., 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

P262 Decreased infliximab trough levels (TLI) is a moderate predictor of loss of response to IFX in IBD patients

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i303-i304

2022

Link zum Volltext

Verfügbarkeit prüfen

P960 Comparison of clinical outcomes by induction therapy response status in patients with Inflammatory Bowel Disease (IBD) treated with subcutaneous (SC) versus intravenous (IV) infliximab (IFX): Post hoc analysis of a pivotal, randomised controlled trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1743-i1744

2024

Link zum Volltext

Verfügbarkeit prüfen

Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Expert opinion on biological therapy, 2021-01, Vol.21 (1), p.97-104

2021

Link zum Volltext

Verfügbarkeit prüfen

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood, 2020-11, Vol.136 (Supplement 1), p.5-6

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Rheumatic & musculoskeletal diseases open, 2019, Vol.5 (1), p.e000876-e000876

2019

Link zum Volltext

Verfügbarkeit prüfen

Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Using LabCorpʼs Electrochemiluminescence Assay (ECLIA) in Inflammatory Bowel Disease Patients: 719

The American journal of gastroenterology, 2017-10, Vol.112, p.S397

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT241: Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT241-CT241

2020

Link zum Volltext

Verfügbarkeit prüfen

Identifying Infliximab- (IFX-) Responsive Blood Signatures for the Treatment of Rheumatoid Arthritis

BioMed research international, 2021, Vol.2021, p.1-10

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26.727

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18.666)
Mit Volltextzugriff
(22.986)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(7.934)
SpringerLink Journals - AutoHoldings
(7.526)
Electronic Journals Library
(7.006)
Journals@Ovid Ovid Full Text
(6.040)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(5.159)
IngentaConnect Journals
(3.528)
Ebook Central Perpetual and DDA
(2.806)
eBooks on EBSCOhost
(2.755)
Nexis Uni
(2.550)
Springer Books
(2.351)
EBSCOhost Business Source Ultimate
(1.973)
Wiley Online Library Journals
(1.826)
Elsevier ScienceDirect Journals Complete
(1.425)
Factiva
(1.417)
Publisher website
(1.386)
ACM Digital Library Complete
(1.265)
Oxford University Press Journals Current
(1.156)
JSTOR Complete Journals
(956)
Wiley Online Library
(905)
Oxford Journals 2020 Medicine
(891)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Crohn's And Colitis
(570)
Annals Of The Rheumatic Diseases
(370)
Mathematics
(325)
Communications Of The Acm
(303)
The American Journal Of Gastroenterology
(287)
Inflammatory Bowel Diseases
(272)
Business Wire
(253)
Gut
(233)
Alimentary Pharmacology & Therapeutics
(222)
Soft Computing
(192)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Mandated Payor Switching With Infliximab (IFX) Biosimilars: 2058

Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy

Iterative Feature eXclusion (IFX): Mitigating feature starvation in gradient boosted decision trees

S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma

Measurements and simulations of surface radiation damage effects on IFX and HPK test structures

Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

EP1311: LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FOLLOWING A SIMPLIFIED PROACTIVE DRUG MONITORING ALGORITHM DURING INDUCTION TREATMENT WITH INFLIXIMAB (IFX)

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy

P430 The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting

P262 Decreased infliximab trough levels (TLI) is a moderate predictor of loss of response to IFX in IBD patients

P960 Comparison of clinical outcomes by induction therapy response status in patients with Inflammatory Bowel Disease (IBD) treated with subcutaneous (SC) versus intravenous (IV) infliximab (IFX): Post hoc analysis of a pivotal, randomised controlled trial

Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Using LabCorpʼs Electrochemiluminescence Assay (ECLIA) in Inflammatory Bowel Disease Patients: 719

Abstract CT241: Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

Identifying Infliximab- (IFX-) Responsive Blood Signatures for the Treatment of Rheumatoid Arthritis

Suchergebnisse filtern